Stockholders Approve 600,000 Share Increase for Equity Plan, Authorize Future Reverse Stock Split

summarizeSummary

Bluejay Diagnostics' stockholders approved a 600,000 share increase for its equity plan, potentially diluting existing shareholders by 58%, and authorized a future reverse stock split as a contingency.

check_boxKey Events

• Stock Plan Share Increase Approved

  Stockholders approved an amendment to the 2021 Stock Plan, increasing the shares reserved for issuance by 600,000, from 61 to 600,061 shares. This represents a potential dilution of approximately 58% of current outstanding shares.

• Future Reverse Stock Split Authorized

  Shareholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-20, giving the Board discretion to implement it within 12 months. The company stated it has no present intention to implement the split and is currently compliant with Nasdaq listing requirements.

• Directors Re-elected

  Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth, and Fred Zeidman were re-elected to the Board of Directors.

• Auditor Ratified

  Wolf & Company, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

auto_awesomeAnalysis

Stockholders approved a significant increase of 600,000 shares for the company's equity incentive plan, representing potential dilution of approximately 58% based on current outstanding shares. This authorization provides substantial headroom for future equity compensation, which will dilute existing shareholders. Additionally, shareholders approved a reverse stock split (1-for-2 to 1-for-20) as a contingency measure, although the company stated it has no present intention to implement it and is currently compliant with Nasdaq listing requirements. This approval provides the board with flexibility to address potential future delisting risks, but the authorization itself can be viewed as a negative signal regarding long-term share price stability.